Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 89.78 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The group usually releases earnings worse than estimated.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
ABBVIE1.59%148 357
MERCK KGAA-7.21%12 543
KYOWA HAKKO KIRIN CO LTD3.24%12 020
JAZZ PHARMACEUTICALS PLC36.04%10 761
ZHANGZHOU PIENTZEHUANG PHAR..77.06%10 382
CONVATEC GROUP10.07%5 660
BETTA PHARMACEUTICALS CO LT..--.--%3 659
INDIVIOR-11.56%3 532
SUPERNUS PHARMACEUTICALS IN..43.16%2 955
YUHAN CORP--.--%2 450
REPLIGEN CORPORATION26.74%2 023
AIMMUNE THERAPEUTICS INC-20.15%1 642
MALLINCKRODT PLC-14.58%1 601
THERAPEUTICSMD INC16.06%1 518
KISSEI PHARMACEUTICAL CO LT..-7.97%1 408
MITHRA PHARMACEUTICALS213.84%1 285
More Results
Financials ($)
Sales 2018 32 922 M
EBIT 2018 14 384 M
Net income 2018 10 789 M
Debt 2018 28 636 M
Yield 2018 3,84%
P/E ratio 2018 13,59
P/E ratio 2019 12,17
EV / Sales 2018 5,38x
EV / Sales 2019 4,97x
Capitalization 148 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBVIE
Duration : Period : Day
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Duration : Period : Week
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders